Most GLP-1 providers
Typical dose-based pricing
+$175/mo more at the top dose
A once-weekly compounded tirzepatide injection, prescribed by a provider as part of a personalized treatment plan.
4-Month Money-Back Guarantee
Try Renlo risk free. If you follow your plan for 4 months and don't see progress, you get a full refund.
Billed monthly. Cancel anytime, no fee.
You could lose up to
Tirzepatide is a once-weekly injectable medication that combines GLP-1 and GIP receptor activity, offering another provider-guided option for sustainable weight management.
Renlo patients report:
Cravings that quiet down fast, with two hormone pathways working together
Fullness that kicks in sooner and sticks around longer
Noticeable progress without extreme swings in appetite or energy
Most GLP-1 providers charge more as your dose increases. Renlo doesn't.
Typical dose-based pricing
+$175/mo more at the top dose
Flat monthly price
$0 increase, at every dose
Price comparison illustrative of typical dose-based pricing in the GLP-1 category. Renlo's compounded products are prepared by a licensed 503A pharmacy.
No insurance, no waiting rooms, no referrals. Get started in minutes and receive your treatment in days.
Answer a few questions about your health and goals. No appointment needed.
A licensed U.S. provider reviews your intake within 12 hours and prescribes treatment if you qualify.
Your medication ships from a licensed U.S. pharmacy directly to your door, free and fast.
Your care team stays with you with unlimited check-ins, adjustments, and answers at no extra charge.
Tirzepatide is a once-weekly injectable medication that combines GLP-1 and GIP receptor activity, offering another provider-guided option for sustainable weight management. Suitability is determined after a licensed provider reviews your intake. Clinical results reflect tirzepatide, the active ingredient - not a guarantee. Renlo's compounded tirzepatide is not the branded product studied in this trial, and individual results vary based on your body, dose, and adherence.
1 Average results in the SURMOUNT-1 trial, New England Journal of Medicine.